RU2009125509A - METHOD FOR TREATING PATIENTS WITH PURLY INFLAMMATORY DISEASES OF THE SKIN - Google Patents
METHOD FOR TREATING PATIENTS WITH PURLY INFLAMMATORY DISEASES OF THE SKIN Download PDFInfo
- Publication number
- RU2009125509A RU2009125509A RU2009125509/15A RU2009125509A RU2009125509A RU 2009125509 A RU2009125509 A RU 2009125509A RU 2009125509/15 A RU2009125509/15 A RU 2009125509/15A RU 2009125509 A RU2009125509 A RU 2009125509A RU 2009125509 A RU2009125509 A RU 2009125509A
- Authority
- RU
- Russia
- Prior art keywords
- bestim
- administered
- days
- treating patients
- daily
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 13
- 208000027866 inflammatory disease Diseases 0.000 title 1
- CATMPQFFVNKDEY-AAEUAGOBSA-N gamma-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-AAEUAGOBSA-N 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 4
- 201000004624 Dermatitis Diseases 0.000 claims abstract 2
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 229940088710 antibiotic agent Drugs 0.000 claims abstract 2
- 239000002504 physiological saline solution Substances 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ лечения больных с гнойно-воспалительными заболеваниями кожи, включающий комплексную терапию с использованием иммунокорректора, отличающийся тем, что в качестве иммунокорректора используют препарат Бестим по крайней мере в течение 5 дней. ! 2. Способ по п.1, отличающийся тем, что Бестим вводят на фоне антибиотиков, противовоспалительных и десенсибилизирующих препаратов. ! 3. Способ по п.1, отличающийся тем, что Бестим вводят перорально в суточной дозе 0,3-1,5 мг в течение 10 дней ежедневно. ! 4. Способ по п.1, отличающийся тем, что Бестим вводят внутримышечно в физиологическом растворе в суточной дозе 0,1 мг. ! 5. Способ по п.4, отличающийся тем, что Бестим вводят внутримышечно 5 раз через день. ! 6. Способ по п.4, отличающийся тем, что Бестим вводят внутримышечно в течение 5 дней ежедневно. 1. A method of treating patients with purulent-inflammatory skin diseases, including complex therapy using an immunocorrector, characterized in that the drug Bestim is used as an immunocorrector for at least 5 days. ! 2. The method according to claim 1, characterized in that Bestim is administered against a background of antibiotics, anti-inflammatory and desensitizing drugs. ! 3. The method according to claim 1, characterized in that Bestim is administered orally in a daily dose of 0.3-1.5 mg for 10 days daily. ! 4. The method according to claim 1, characterized in that Bestim is administered intramuscularly in physiological saline in a daily dose of 0.1 mg. ! 5. The method according to claim 4, characterized in that Bestim is administered intramuscularly 5 times every other day. ! 6. The method according to claim 4, characterized in that Bestim is administered intramuscularly for 5 days daily.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009125509/15A RU2423976C2 (en) | 2009-06-25 | 2009-06-25 | Method of treating patients with pyoinflammatory skin diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009125509/15A RU2423976C2 (en) | 2009-06-25 | 2009-06-25 | Method of treating patients with pyoinflammatory skin diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009125509A true RU2009125509A (en) | 2010-12-27 |
| RU2423976C2 RU2423976C2 (en) | 2011-07-20 |
Family
ID=44055497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009125509/15A RU2423976C2 (en) | 2009-06-25 | 2009-06-25 | Method of treating patients with pyoinflammatory skin diseases |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2423976C2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2120298C1 (en) * | 1995-11-28 | 1998-10-20 | Товарищество с ограниченной ответственностью "Верта" | Immunostimulating agent and a preparation based on thereof |
-
2009
- 2009-06-25 RU RU2009125509/15A patent/RU2423976C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2423976C2 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690069A1 (en) | THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE | |
| EA200800881A1 (en) | DOSAGE FORM OF PYRFENIDONE IN THE FORM OF CAPSULES WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS | |
| RU2013123646A (en) | COMBINED COMPOSITION | |
| JP2013155188A5 (en) | ||
| EA201290171A1 (en) | INTRODUCED ORAL CORRECTIC STERILE COMPOSITIONS | |
| EA201270144A1 (en) | COMBINED THERAPY FOR TREATMENT OF DIABETES | |
| RU2014150942A (en) | TREATMENT OF SIDE EFFECTS IN THE FORM OF MOTOR AND MOTOR DISORDERS RELATED TO THE TREATMENT OF PARKINSON'S DISEASE | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| AR090885A1 (en) | USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| RU2013127420A (en) | WAYS TO REDUCE PSYCHOGENIC OR COMPULSIVE Overeating | |
| RU2012108656A (en) | APPLICATION OF 4-AMINOPYRIDINE TO IMPROVE CONDITION IN NEURO-COGNITIVE AND / OR NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH DEMILINIZING AND OTHER DISEASES OF THE NERVOUS SYSTEM | |
| RU2009101026A (en) | APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV | |
| RU2013105513A (en) | Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases | |
| RU2353358C2 (en) | Pregabalin derivatives for hot flush treatment | |
| RU2009125509A (en) | METHOD FOR TREATING PATIENTS WITH PURLY INFLAMMATORY DISEASES OF THE SKIN | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| RU2006126471A (en) | METHOD FOR TREATING INFLAMMATORY DISEASES OF THE SALIVARY GLANDS | |
| RU2011121219A (en) | METHOD FOR TREATING INFLAMMATORY DISEASES OF THE PARADONT | |
| RU2011111673A (en) | METHOD AND MEANS FOR THE TREATMENT OF EXUSDATIVE MIDDLE OTITIS | |
| EA201592261A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING AGOMELATIN IN THE FORM OF HOMELATIN CRYSTALS WITH ORGANIC ACID | |
| AR096674A1 (en) | TREATMENT METHOD OF A HUMAN PATIENT SUFFERING FROM HUNTINGTON'S DISEASE | |
| RU2010129491A (en) | METHOD FOR TREATMENT AND PREVENTION OF DENTAL CARIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140626 |